A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
about
Oncolytic adenovirus-mediated therapy for prostate cancerChapter two--Adenovirus strategies for tissue-specific targeting.A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancerCombination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.The evolution of adenoviral vectors through genetic and chemical surface modifications.Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy.Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.Gene Therapy Used in Cancer Treatment.
P2860
Q27004796-C1D157E4-6F94-4CE3-A384-D371A52134A4Q34643252-0C62725A-20B4-46D3-A1E6-05F036BB8F27Q35874291-91070F49-DECC-4100-8878-0C4EC994C100Q36220624-7FAA31BE-6F84-451F-87D8-0B6992853DDDQ37107332-12C87E90-F52E-4FA6-BCA4-DFD63DF14935Q37362758-36F3827F-0603-4513-A280-C9D6FF83A76AQ38033591-642012EF-5B66-4BA9-90D9-25AD30E2C98EQ38189250-0508352B-8AA7-475A-8119-572CA1F254E2Q38714311-A9C02AE1-0E1B-4DCD-A159-49FA51CF7957Q38769919-478024A6-A82C-4C50-9116-65DCEC38D319Q38949072-881ED083-C463-4171-ABA3-AF9BB8A99E69Q51846343-59A8493E-0D64-48CE-AC8F-F86EFA66BC1C
P2860
A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A new generation of serotype c ...... al in ovarian cancer patients.
@ast
A new generation of serotype c ...... al in ovarian cancer patients.
@en
type
label
A new generation of serotype c ...... al in ovarian cancer patients.
@ast
A new generation of serotype c ...... al in ovarian cancer patients.
@en
prefLabel
A new generation of serotype c ...... al in ovarian cancer patients.
@ast
A new generation of serotype c ...... al in ovarian cancer patients.
@en
P2093
P2860
P50
P356
P1433
P1476
A new generation of serotype c ...... al in ovarian cancer patients.
@en
P2093
Brock M Miniard
James E Estep
James O Peggins
Kenneth H Kim
Meredith A Preuss
Michael J Ryan
Minghui Wang
Raymond D Harris
Ronald D Alvarez
Rosemarie Aurigemma
P2860
P304
P356
10.1089/HUM.2010.180
P577
2011-03-23T00:00:00Z